Authors

How Does the Shift to Early-Stage M&A Change Due Diligence?

A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Making an Impact in the Era of Disinformation

With increasing cases of disinformation across social media blurring the lines of what’s credible and real, how can pharma break through the noise and build back public trust?

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Powering Pipelines Forward: Approach Science Differently

Why tapping the value generated for the next set of therapies is critical.

Exploring Biopharma's Dealmaking Terrain, Roadmap in China

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

'Discovery to Delivery': How BPD Buy Helps MJH Bridge Science of Discovery With The Systems That Deliver Care

In this video discussion with Pharmaceutical Executive, Michael J. Hennessy Jr., chairman and CEO of MJH Life Sciences, and Jason Brown, CEO of BPD Healthcare, discuss how the deal came together and what it means for healthcare executives navigating an increasingly complex marketplace.

Transforming Healthcare: Beyond Buzzwords to Purposeful Change

For a growth mindset to truly take hold, leaders must create space for those possibilities to thrive.

Final Thoughts

The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.

Navigating the Complexities of a Global Pharma Expansion

A case study in leading and guiding a cultural reset and strategic revival.

Using AI to Predict Launch Success

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

The booming obesity drug market is redefining prescriber influence, with nurse practitioners and physician associates emerging as key decision-makers that life sciences marketers can no longer afford to overlook.

Real-Time Measurement of EPA Regulated HON Compounds and Environmental Pollutants Using SIFT-MS

This application note summarizes key SIFT-MS results presented in a peer reviewed article entitled “Unreported VOC Emissions from Road Transport Including from Electric Vehicles.” Learn how the Wolfson Atmospheric Chemistry Laboratory at the University of York used SIFT-MS for VOC analysis in its platform to experimentally verify that motor vehicle screen wash is a significant unreported source of VOC emissions (especially for ethanol and methanol).

9 Ways To Use Microlearning To Train Life Sciences Commercial Teams

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

From Advantage to Essential: How Daily Data & AI Alerts Transform Commercial Functions

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Pharma Forecasting: Key Markets Investors Can’t Ignore

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Maintaining Supply Chain Resiliency, No Matter the Circumstances

The formula for future-proofing pharmaceutical networks to withstand any disruption.

The 8 Market Access Performance Metrics You Should Be Tracking

This guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.

Sustainability and Progress Continue to Make Headlines in 2024

Recognition of the business case for ESG in pharma is soaring.

Translating ‘Digital-First’ to Commercial Success

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

Approaching Agentic AI Strategically: Life Sciences Data Utilization

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations

An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

What Innovation in PBM Management Really Looks Like

The quest to align cost with care, enhance data visibility, and shed the dependence on outdated revenue streams.

Biopharma Needs a Health System Strategy to Secure Optimal Market Access

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

Rethinking Audience Modeling: AI, Regulations, & More

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.